NEC Baby Formula Lawsuit 2026: 844 Cases Pending, the $670M Abbott Settlement & Who Can Still File
As of October 2026, 844 NEC baby formula lawsuits remain pending in the federal multidistrict litigation, and Abbott has agreed to a $670 million settlement covering part of the claims. New trials and appeals keep reshaping the litigation, and families of premature infants who developed necrotizing enterocolitis after formula feeding can still file claims in 2026.
Key Facts
- 844 actions were pending in MDL 3026 in the JPML's October 1, 2026 statistics report.
- Abbott announced a $670 million settlement on August 20, 2026, covering about 2,000 people — without admitting liability.
- A Missouri jury awarded $495 million against Abbott in July 2024 ($95 million compensatory, $400 million punitive), upheld on appeal in May 2026.
- A Cook County jury awarded $70 million to four families in April 2026; Abbott plans to appeal.
- Federal cases have been centralized in MDL 3026 in the Northern District of Illinois before Judge Rebecca R. Pallmeyer since April 8, 2022.
What the NEC Lawsuits Actually Claim
NEC — necrotizing enterocolitis — is a serious intestinal disease that primarily strikes premature infants, in which portions of the bowel tissue die. The lawsuits allege that cow's-milk-based preterm infant formulas and fortifiers, including products sold under the Similac and Enfamil brands, increased the risk of NEC in premature babies, and that the manufacturers failed to warn hospitals and parents adequately.
Abbott Laboratories (Similac) and Mead Johnson (Enfamil) deny the claims and maintain their products are safe. Federal health agencies add an important scientific distinction: there is no conclusive evidence that preterm infant formula itself causes NEC, while strong evidence supports a protective role for human milk. The litigation therefore turns on what the companies knew and whether their warnings were adequate — not on a blanket finding about formula.
The Trial Record So Far: Wins on Both Sides
Six jury verdicts have been reached through September 2026, cutting in both directions. Plaintiffs won three significant ones: a Missouri jury awarded $495 million against Abbott in the Gill case in July 2024 (upheld by the Missouri Court of Appeals in May 2026), an Illinois jury awarded $60 million against Mead Johnson in the Watson case in March 2024, and a Cook County jury awarded $70 million to four families in April 2026.
The defense has won too — including on appeal. The $60 million Watson verdict was reversed by the Illinois Appellate Court in June 2026, which ordered a new trial over faulty jury instructions. Abbott won a St. Louis trial in October 2024 (later set aside for a new trial), won the Collins trial in July 2026, and Mead Johnson won the first federal bellwether — Inman, decided August 31, 2026 — with a unanimous defense verdict.
Abbott's $670 Million Settlement — What It Covers
On August 20, 2026, Abbott announced a $670 million settlement with three law firms representing about 2,000 people. Abbott did not admit liability, agreed to drop its appeal of the St. Louis verdict, and said it remains confident in the safety of its products.
Critically, the settlement is partial. It does not cover Mead Johnson or Enfamil claims — Mead Johnson has announced no settlement and, after winning Inman, says it will defend every claim. The product your child was fed determines which path your claim follows. For a clear explainer of how these consolidated cases move from filing to trial, see our coverage of the Tylenol autism litigation revival.
Where MDL 3026 Stands Now
The federal cases sit before Judge Rebecca R. Pallmeyer with 844 actions pending. The bellwether process — representative trials meant to test both sides' cases — has produced uneven results: Abbott won the first three scheduled federal bellwethers on summary judgment, while Mead Johnson's Inman case reached a defense verdict at trial. The next trial, Kelton v. Abbott, was set for October 15, 2026.
In October 2026, the judge questioned whether continuing the bellwether process will actually resolve the cases, suggesting the litigation could focus more on state courts, where plaintiffs have seen more success. And on July 28, 2026, the Seventh Circuit reversed and remanded five jurisdictional cases, keeping additional claims alive.
Who Can Still File — and What You Must Prove
New claims are still being filed, generally involving premature infants fed cow's-milk-based formula or fortifier in a hospital NICU who subsequently developed NEC. Parents and guardians file on the child's behalf. Deadlines vary by state, and the rules for claims filed for minors differ from ordinary injury claims — waiting rarely helps, because hospital records become harder to obtain over time. For context on how concluded litigations treat late claims, see what happened after the Zofran litigation ended.
NEC cases are document-heavy, and product identification is critical: you must show your child was fed the specific defendant's product. The records that matter are NICU records documenting feeding type, gestational age documentation, the NEC diagnosis and any surgical records, pathology reports, and feeding logs naming the exact product. Cases also require medical causation evidence linking the child's NEC to the formula — which is why the defense verdicts have centered on expert testimony.
What to Do Next
If your premature infant developed NEC after being fed Similac or Enfamil products: request the complete NICU records now, note the exact products and dates, and speak with an attorney experienced in NEC or mass-tort litigation about your state's deadline. Most work on contingency — nothing upfront.
Two cautions. First, the August 2026 settlement covers only some Abbott claims; do not assume your claim is included. Second, financing a long case is its own decision — our guide to pre-settlement lawsuit loans explains the costs and alternatives before you borrow against a future recovery. For video explainers on consumer legal topics, visit Problem Solved on YouTube.
Who Benefits From This — and Who Does Not
Who benefits most from this guide:
Parents or guardians of a premature infant fed cow's-milk-based formula or fortifier in a hospital NICU who then developed NEC How: new claims are still being filed on that pattern, and parents and guardians file on the child's behalf
Families who can produce NICU records naming the exact product How: product identification is critical: NICU records documenting feeding type, gestational age documentation, the NEC diagnosis and any surgical records, pathology reports, and feeding logs naming the exact product
Families whose claims fall outside the August 2026 Abbott settlement How: that $670 million settlement covers only some Abbott claims, with about 2,000 people represented by three law firms, and does not cover Mead Johnson or Enfamil claims, while unresolved claims continue and MDL 3026 lists 844 pending actions as of October 1, 2026
Who does not benefit:
Anyone assuming the Abbott settlement covers their claim automatically How: the August 20, 2026 settlement covers only some Abbott claims and does not cover Mead Johnson or Enfamil claims
Anyone who cannot show the child was fed the specific defendant's product How: cases require showing the child was fed that defendant's product, plus medical causation evidence linking the child's NEC to the formula
Anyone who waits while hospital records age How: deadlines vary by state, the rules for claims filed for minors differ from ordinary injury claims, and hospital records become harder to obtain over time
For what happens to late claims once a litigation has concluded, see our Zofran litigation report.
Frequently Asked Questions
How many NEC baby formula lawsuits are pending in 2026?
The JPML's October 1, 2026 statistics report lists 844 pending actions in MDL 3026. Abbott has said roughly 1,700 lawsuits remain across state and federal courts, covering about 12,700 infants.
Did Abbott settle the NEC baby formula lawsuits?
Partially. On August 20, 2026, Abbott announced a $670 million settlement with three law firms representing about 2,000 people, without admitting liability. It does not cover Mead Johnson or Enfamil claims, and unresolved claims continue.
What does the science say about formula and NEC?
Federal health agencies state there is no conclusive evidence that preterm infant formula itself causes NEC, while strong evidence supports a protective role for human milk. The lawsuits focus on whether manufacturers adequately warned about the risks.
Who qualifies to file an NEC baby formula claim?
Generally, parents or guardians of a premature infant fed cow's-milk-based formula (such as Similac or Enfamil preterm products) in a NICU who then developed necrotizing enterocolitis. An attorney can assess your records and your state's deadline.
This article provides general information only and is not legal or medical advice. Litigation facts change; consult a qualified attorney about your situation.
Who benefits from an NEC baby formula claim, and who does not?
Parents or guardians of a premature infant fed cow's-milk-based formula or fortifier in a NICU who then developed NEC benefit most, especially when NICU records name the exact product and document gestational age, the NEC diagnosis, and feeding logs. People assuming the $670 million Abbott settlement covers them automatically do not benefit, since it covers only some Abbott claims and not Mead Johnson or Enfamil claims, and neither does anyone who cannot show the child was fed the specific defendant's product.
How do I start an NEC baby formula claim?
Request the complete NICU records now, note the exact products and dates, and speak with an attorney experienced in NEC or mass-tort litigation about your state's deadline. Most work on contingency, with nothing upfront, and do not assume your claim is included in the August 2026 Abbott settlement.